SMS Pharmaceuticals Share Price

SMS Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs) and its intermediates in India and internationally. It is also involved in contract research activities on peptides. The company exports its products to approximately 75 countries. SMS Pharmaceuticals share price on the NSE and BSE is a reflection of how market participants respond to a company’s performance and broader business developments within its industry. It captures the sentiment of the investors based on financial results, operational updates, macroeconomic factors, and trends specific to sectors. Movements in the share price͏ reveal how the market evaluates the company’s current position and its future prospects, making ͏it a key indicator of market perception across various industries. 

SMS Pharmaceuticals stock price is influenced by various factors such as earnings growth, regulatory approvals from bodies like the USFDA, research and development outcomes, and global API supply chain dynamics. Over the long term, strategies focusing on capacity expansion, product portfolio diversification, and growth in export markets affect investor sentiment. All these factors must be closely monitored to have an idea about the SMS Pharmaceuticals stock price movements.  

SMS Pharmaceuticals live share price provides real-time information about the last price traded, bid price, ask price, and volume traded. These indicators represent trading activity and liquidity and the reaction of investors to corporate announcements, quarterly results, and sector news. Constant ͏monitoring of SMS Pharmaceuticals live price helps observe short-term price fluctuations and understand how the stock is moving in relation to the broader market. 

Furthermore, monitoring the SMS Pharmaceuticals share͏ price today helps investors understand real-time market sentiment, price volatility, and trading behaviour. It allows market participants to evaluate short-term performance, identify possible entry or exit points, and respond to news, quarterly results or sector trends that may affect the company’s valuation and overall investment outlook. 

SMS Pharmaceuticals Ltd Company Fundamentals 

SMS Pharmaceuticals Company Background 

SMS Pharmaceuticals Ltd operates as a pharmaceutical manufacturing company in India with facilities that comply with cGMP and WHO standards. The company is engaged in the manufacturing of active pharmaceutical ingredients (APIs) and is supported by dedicated research and manufacturing teams and established infrastructure. 

Founded in 1990 as a single-facility, single-product operation, SMS Pharmaceuticals has expanded over the years into a multi-location group with a product portfolio covering several therapeutic segments. The company received export house status in 1997–98, reflecting the growth of its overseas operations. 

SMS Pharmaceuticals is a listed entity and serves both international and domestic customers. Its operations currently include four multi-product manufacturing facilities and two research centres. The organisation employs over 1,000 people across its manufacturing, research, and support functions. 

SMS Pharmaceuticals Company Product Lines 

• Active Pharmaceutical Ingredients (APIs) across 14+ therapeutic segments, including anti-diabetic, anti-epileptic, anti-ulcer, anti-migraine, anti-retroviral, anti-inflammatory and more.  
• Intermediates used in API synthesis and pharmaceutical production.  
• Contract Research and Manufacturing Services (CRAMS) including custom synthesis and process development.  
• Analytical & laboratory services supporting quality testing (assays, impurities, dissolution, content uniformity).  
• Regulatory support services related to global compliance. 

SMS Pharmaceuticals Company Revenue Model 

• API Sales: Core revenue from manufacturing and selling APIs and intermediates to international generic and innovator pharma firms.  
• Exports: Majority of revenue from exports — around 88% of total sales in FY2024–25.  
• Contract Manufacturing (CRAMS): Revenue from outsourced manufacturing and development projects.  
• Global B2B supply: Long-term supply agreements with major pharmaceutical companies globally.  

SMS Pharmaceuticals Geographic Presence 

• Manufacturing Units: 
• Bachupally, Hyderabad (APIs & intermediates).  
• Vizianagaram, Andhra Pradesh (large-scale API manufacturing).  
• Exports to over 75+ countries worldwide 

SMS Pharmaceuticals Leadership  

Some of the key leaders of SMS Pharmaceuticals Limited as of February 2026 are 

• P. Ramesh Babu – Chairman & Managing Director 
• Vamsi Krishna Potluri – Executive Director 
• Thirumalesh Tumma – Company Secretary & Compliance Officer 
• Shravan Kudaravalli – Independent Director 
• Thummala Neelaveni – Independent Director 
• P. Sarath Kumar – Independent Director 
• Sarvepalli Srinivas – Independent Director 
• G. Suresh Kumar – Independent Director 
• Lakshmi Narayana Tammineedi – Chief Financial Officer 
• Thirumalesh Tumma – Company Secretary & Compliance Officer 
• NHD Prasad – Vice President (Operations) 
• G. Srinivasa Rao – Assistant General Manager (Production) 
• Dr. T. V. Vidya Sagar – Deputy General Manager (AR&D, Central Laboratory) 

 SMS Pharmaceuticals Key Milestones 

• 1987: Incorporated in December and commenced operations in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. 
• Early Years: Established an R&D Centre at Gagillapur, Hyderabad, and manufacturing facilities at Bachupally, Hyderabad, and Kandivalasa village, Vizianagaram district, Andhra Pradesh. 
• 2014–15: Acquired 12,25,900 equity shares in VKT Pharma Private Limited, making it an associate company. 
• 2015: Successfully completed US FDA audits at Kandivalasa and Bachupally manufacturing facilities, reinforcing compliance standards. 
• 2015: Filed 9 Drug Master Files (DMFs), taking the total DMFs filed to 24 as of 31 March 2015. 
• 2015–16: Subdivided equity shares from face value of ₹10 to ₹1, with record date of 18 December 2015. 
• 2015–16: Approved a draft scheme for demerger of semi-regulated units to SMS Lifesciences India Limited to improve operational efficiency. 
• 2016–17: Invested further in VKT Pharma Private Limited and made an initial investment in Sireen Drugs Private Limited. 
• 2017: Demerger of semi-regulated units became effective from 17 May 2017; SMS Lifesciences India Limited became a wholly owned subsidiary. 
• 2017–18: Increased stake in VKT Pharma Private Limited through additional equity acquisition. 
• 2018–19: Continued investment in VKT Pharma Private Limited, holding 38,50,165 equity shares as of 31 March 2019. 
• 2020–21: Incorporated a joint venture in Spain, CHEMO SMS ENTERPRISES SL, in a 55:45 ratio. 
• 2023: Launched Ibuprofen product through the Spain joint venture. 
• 2025: Expanded Ibuprofen production capacity by 1,300 KL at the Visakhapatnam facility and strengthened presence in high-value API segments. 

Industry Perspective 

Based on its core activities in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs), SMS Pharmaceuticals Limited operates within the global pharmaceutical manufacturing and contract development and manufacturing organization (CDMO) industry. This industry is the backbone of global healthcare, producing the essential chemical and biological substances for medicines. Driven by rising chronic disease prevalence, aging populations, and growing generic drug demand post-patent expiries, the market is on a strong growth trajectory. The Active Pharmaceutical Ingredients Market size is estimated at USD 245.67 billion in 2026, and is expected to reach USD 348.61 billion by 2031, at a CAGR of 7.25% during the forecast period (2026-2031). The CDMO segment, benefiting from pharmaceutical companies outsourcing for cost efficiency, is expanding even faster. The small molecule API CDMO market alone is expected to grow from $100.4 billion in 2024 to $137.7 billion by 2029, at a CAGR of 6.5%. 

The positive industry tailwinds directly benefit SMS Pharma. The projected CAGR in the global API market, especially in high-growth CDMO and specialty segments, aligns with its core business. This expanding market provides a larger revenue base, validates its strategic investments in niche APIs (like oncology), and enhances opportunities for long-term contracts with global innovators seeking reliable, cost-effective manufacturing partners. 

 SMS Pharmaceuticals Ltd Stock Market Presence: Listings & Index Representation 

SMS Pharmaceuticals Limited is listed on the BSE (Bombay Stock Exchange) and the NSE (National Stock Exchange). Its BSE Scrip Code is 532815 and its NSE Symbol is SMSPHARMA. 

SMS Pharmaceuticals Limited is an established entity in the Indian stock market. Its inclusion in prominent sectoral indices like the S&P BSE Healthcare, S&P BSE SmallCap, S&P BSE MidSmallCap, and S&P BSE AllCap underscores the company’s significance within India’s pharmaceuticals and healthcare sector. 

The SMS Pharmaceuticals stock price is tracked by investors focused on the pharmaceutical manufacturing space. Its inclusion in these indices reflects the company’s market capitalisation, compliance with stringent global regulatory standards, and its scale in API manufacturing and exports. Listing on the NSE and BSE ensures liquidity, while its presence in healthcare-focused indices attracts institutional attention and highlights its role in a critical sector of the economy. 

SMS Pharmaceuticals Ltd Stock Performance and Share Price History 

The SMS Pharmaceuticals share price on NSE and BSE reflects its position as a key player in the API manufacturing segment. Its performance is driven by factors like revenue growth, margin stability, regulatory compliance at its facilities, and successful research and development efforts. Investors often compare the SMS Pharmaceuticals share price today with sectoral indices like S&P BSE Healthcare and peers to gauge relative performance. 

These underlying operational factors manifest in real market movements across periods. For instance, strong performance is frequently observed around positive earnings announcements or regulatory approvals. Broader sectoral trends, such as increased global demand for APIs or government support for bulk drug manufacturing, have also played a role in supporting the SMS Pharmaceuticals share price. Corporate actions, including fundraising or strategic expansions, can trigger significant short-term swings in the SMS Pharmaceuticals share price, even when the company’s long-term fundamentals remain steady. 

While short-term movements reflect specific events, longer-term valuation trends are visible through the SMS Pharmaceuticals share price 52-week high and low, providing context beyond daily changes. Highs can indicate periods of strong earnings growth, successful product launches, or favourable sector tailwinds, while lows often align with broader market corrections, sector-specific challenges, or periods of compressed margins. These levels capture the impact of operational performance, regulatory developments, and growth expectations, offering a clear view of the stock’s historical trading range. 

The stock performance of SMS Pharmaceuticals reflects the trading patterns of a mid-sized pharmaceutical company operating in a competitive and regulated global industry. The company’s focus on a diversified API portfolio, investments in research and development, and a growing export footprint have shaped its SMS Pharmaceuticals share price history. Over time, the stock has demonstrated growth potential, marked by phases of sharp appreciation and periods of consolidation. 

A review of historical returns data reveals distinct performance cycles. The stock delivered exceptional returns of 187.64% in the calendar year 2020, driven by heightened global demand for pharmaceuticals during the COVID-19 pandemic. This was followed by a correction of -35.21% in 2022, a period marked by post-pandemic normalization, rising input costs, and broader market volatility. A powerful recovery began in 2023, with the stock surging 43.37%, and accelerated dramatically in 2024 with a gain of 100.55%, supported by strong financial performance and positive sector sentiment. This momentum has continued into 2025. 

The SMS Pharmaceuticals stock price over time has responded to company-specific milestones and economic cycles. For example, the SMS Pharmaceuticals share price reached a significant high in recent periods, supported by consistent revenue growth and investor confidence in its expansion plans. Over defined investment horizons, the stock has delivered substantial returns, including a gain of 324.73% over three years and 166.02% over five years, as per recent data. These returns highlight a period of significant growth aligned with the company’s operational execution and strategic initiatives. 

The SMS Pharmaceuticals share price demonstrated resilience during the global pandemic, a period that underscored the critical nature of the pharmaceutical supply chain. While the sector faced logistical and cost challenges, the company’s established manufacturing base and essential product portfolio helped it navigate the period. Subsequent investments and a focus on backward integration have been viewed positively by the market, contributing to stability and subsequent growth in the SMS Pharmaceuticals stock price in the years that followed. 

SMS Pharmaceuticals Ltd Investor Relevance and Portfolio Role 

SMS Pharmaceuticals can be considered a strategic holding in sector-specific and small-to-mid-cap portfolios, offering exposure to the essential API manufacturing segment of the Indian pharmaceutical industry. Its inclusion in key indices like S&P BSE Healthcare underscores its relevance within this critical sector. A focus on regulatory compliance, research and development, and export growth contributes to its profile for investors seeking pharmaceutical manufacturing exposure. 

SMS Pharmaceuticals equity is held by a mix of domestic mutual funds and international ETFs that target Indian healthcare or broader emerging markets. Top mutual fund holders include Quant Mutual Fund (through its Small Cap Fund and Healthcare Fund), Motilal Oswal Mutual Fund (via its BSE Healthcare ETF), and Bandhan Mutual Fund (through its BSE Healthcare Index Fund). International holders include funds like the American Century ETF Trust’s Avantis Emerging Markets Small Cap Equity ETF. This investor base highlights the stock’s role as a targeted holding within healthcare and emerging market portfolios. 

Technical indicators such as the SMS Pharmaceuticals RSI, MACD, and MFI provide additional insight into short-term momentum shifts in the SMS Pharmaceuticals stock price. While primarily used for near-term trading analysis, these tools can help market participants gauge sentiment and potential volatility around corporate events or earnings releases. 

The beta of SMS Pharmaceuticals indicates its volatility relative to the broader market. Available data shows a long-term beta of 1.26, suggesting the stock has historically been more volatile than the market. This beta value fluctuates across different time frames; for instance, the daily beta over a one-month range was 0.229, indicating low short-term correlation, while weekly and monthly measures over one and two-year ranges show higher beta values between 1.92 and 2.22. This range of beta values reflects the stock’s sensitivity to market movements, which can vary significantly depending on the measurement period and prevailing market conditions. Monitoring these metrics helps in understanding the potential risk and volatility profile associated with the SMS Pharmaceuticals share price. 

SMS Pharmaceuticals Ltd Sectoral Relevance and Peer Positioning 

SMS Pharmaceuticals’ sector relevance stems from its integrated operations in API manufacturing, regulatory track record with agencies like the USFDA, and its role in the essential pharmaceutical supply chain. Peer comparisons with other API and formulation companies such as Divi’s Laboratories, Solara Active Pharma Sciences, Granules India, Laurus Labs, and Aarti Drugs often focus on parameters like revenue growth, product portfolio diversity, export market penetration, and research and development expenditure rather than short-term stock price movements. These benchmarks help assess operational scale, manufacturing efficiency, and compliance adherence. Institutional tracking of API pricing trends, capacity utilization, and regulatory developments further highlights the company’s strategic position within India’s broader pharmaceuticals market. 

SMS Pharmaceuticals market cap history demonstrates its growth trajectory and changing investor valuation. As of February 2026, its market cap stood at approximately ₹29.51 billion, representing an increase of 57.70% over one year. This follows substantial growth from ₹7.01 billion in December 2022 to ₹20.22 billion in December 2024, culminating in a value of ₹29.07 billion by December 2025. Since its listing in 2007, the company’s market cap has grown from ₹2.67 billion to its current level, reflecting a compound annual growth rate of approximately 13.53% over this extended period and underscoring long-term value creation. 

SMS Pharmaceuticals earnings shows a pattern of growth with periodic volatility. Net income grew from ₹31.57 crore in March 2020 to ₹62.53 crore in March 2021, reflecting strong pandemic-era demand. A significant downturn occurred in March 2023, with a net loss of ₹-7.06 crore, attributed to challenging market conditions and increased costs. A robust recovery followed, with net income jumping to ₹49.83 crore in March 2024 and further to ₹69.14 crore in March 2025. This recent performance indicates a strong rebound in profitability, driven by improved operational execution and favourable market dynamics for its product portfolio. 

SMS Pharmaceuticals EPS mirrors its net income trajectory, providing a per-share perspective on profitability. EPS was ₹3.73 in March 2020, rose to ₹7.39 in March 2021, and remained stable at ₹7.35 in March 2022. A sharp decline led to negative EPS of ₹-0.83 in March 2023. The recovery phase saw EPS rebound to ₹5.89 in March 2024 and further improve to ₹8.16 in March 2025. This EPS history highlights the company’s ability to recover from downturns and deliver growing earnings on a per-share basis, which is a critical driver for the SMS Pharmaceuticals share price over the long term. 

SMS Pharmaceuticals P/E ratio illustrates how market valuation has shifted alongside its earnings. The P/E ratio was 7.21 in March 2020, increased to 16.84 in March 2021, and was 12.72 in March 2022. A notable anomaly occurred in March 2023, where the P/E turned highly negative (-70.18) due to the reported net loss. As earnings recovered, the P/E ratio normalized to 30.26 in March 2024 and adjusted to 26.08 by March 2025. The trailing twelve-month P/E ratio was reported as 33.13, indicating the market’s current valuation of the company’s earnings stream. 

Summary 

SMS Pharmaceuticals Limited is a significant Indian company engaged in the manufacturing of active pharmaceutical ingredients (APIs). The SMS Pharmaceuticals share price is influenced by its financial performance, regulatory milestones, and trends in the global pharmaceutical sector. Investors monitor its market presence, historical performance, and sectoral positioning to inform their perspective. The company holds a specific role within healthcare-focused investment portfolios.